Inhibitory effects of hypertonic saline on P. aeruginosa motility.
Salt transport defects in CF lungs predispose to overwhelming and fatal respiratory infection caused by Pseudomonas aeruginosa. Motility of this organism is central to pathogenesis in a number of settings. Incubation of numerous strains of P. aeruginosa with hypertonic saline caused a concentration-dependent decrease in bacterial motility. Reduction of P. aeruginosa virulence through this effect may contribute to clinical efficacy of hypertonic saline aerosols in CF patients.
Havasi
Viktória
V
Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, 1918 University Boulevard, Birmingham, AL 35294-0005, United States. Electronic address: vhavasi@uab.edu.
Hurst
Casey O
CO
Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, 1918 University Boulevard, Birmingham, AL 35294-0005, United States.
Briles
Travis C
TC
Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, 1918 University Boulevard, Birmingham, AL 35294-0005, United States.
Yang
Fan
F
Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, 1918 University Boulevard, Birmingham, AL 35294-0005, United States.
Bains
David G
DG
Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, 1918 University Boulevard, Birmingham, AL 35294-0005, United States.
Hassett
Daniel J
DJ
Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0524, United States.
Sorscher
Eric
E
Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, 1918 University Boulevard, Birmingham, AL 35294-0005, United States.
D000280:Administration, Inhalation; D000890:Anti-Infective Agents / Q000494:pharmacology*; D018441:Biofilms / Q000187:drug effects; D002633:Chemotaxis / Q000187:drug effects; D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy*; D005407:Flagella / Q000187:drug effects*; D006801:Humans; D011552:Pseudomonas Infections / Q000150:complications / Q000517:prevention & control; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000502:physiology; D012141:Respiratory Tract Infections / Q000150:complications / Q000517:prevention & control; D012462:Saline Solution, Hypertonic / Q000494:pharmacology*
D000890:Anti-Infective Agents; D012462:Saline Solution, Hypertonic